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Dr Charles Brantigan (Denver, Colo). I’d like to know how
you made the diagnosis of the various types of Ehlers-Danlos. Was
the diagnosis based on genetic testing, or was it based on clinical
presentation? If you’re faced with a patient with what looks like
Ehlers-Danlos syndrome that might need a vascular procedure,
what further diagnostic tests are needed?
Dr Brooke.When vascular surgeons are referred patients with
Ehlers-Danlos, there is usually a lot of confusion as to how to
distinguish the different subtypes. However, most patients can be
reliably diagnosed solely on clinical grounds using the revised
diagnostic criteria from the nosology of Villefranche. If a diagnosis
of vascular type Ehlers-Danlos needs to be confirmed, skin biopsies
can be obtained to assay the amount of type III collagen levels from
dermal fibroblasts. Alternatively, PCR analysis may also be em-
ployed to look for collagen III mutations. Finally, it always helps to
consult a trained medical geneticist to assist with making the
diagnosis.
Dr B. Timothy Baxter (Omaha, Neb). I have a fair expe-
rience with these patients. I just have a couple comments and
questions.
I think that the older the patients are at the time they
present, the less I worry. I think their tissues are going to be
better if they present at an older age. The young patients are the
ones that the tissues can be more difficult. Can you comment on
this?
My other question is about surveillance in these patients. One
of the problems that you pointed out is that most of these are
women. I am reluctant to do frequent CT scans in these patients
because of the radiation risk especially associated with breast can-
cer. I have followed them with MRI.
The last question is, do you routinely do any intracranial
scanning to look for intracranial aneurysms or associated pathology
that might need to be addressed?
Dr Brooke. There is not a clear genotype-phenotype correla-
tion with Ehlers-Danlos syndrome, and patients of all ages and
subtypes can behave very differently in an operative setting. Older
patients with EDS who haven’t experienced a major vascular
complication may indeed have good tissue characteristics for elec-
tive procedures, but this is hard to generalize.
In our cohort, some of the oldest patients underwent the
endovascular procedures. Conversely, we worry that younger pa-
tients who present with vascular complications at an early age are
going to have poor tissue characteristics and may be at higher risk
for poor outcomes. We recognize that better methods are needed
for stratifying Ehlers-Danlos patients’ operative risk based on
variables including their age, comorbidities, family history, tissueWith regard to your second question about surveillance, we
employ a similar strategy that includes CT angiography, MRI/
MRA in special circumstances, and occasionally, ultrasound for
transcranial assessment.
We routinely assess intracranial imaging in patients when
the diagnosis of Ehlers-Danlos is in question. Patients with a
similar connective tissue disease known as Loeys-Dietz syn-
drome have a propensity for arterial tortuosity within their
vertebral and carotid vasculature. Hence, this radiographic find-
ing can help establish the diagnosis of Loeys-Dietz versus the
vascular type of Ehlers-Danlos.
Dr Ronald Dalman (Palo Alto, Calif). I noticed that most of
your patients that were treated were treated with embolization.
I’m curious how you approach more complex problems that don’t
necessarily lend themselves to embolization. For example, I have
one patient with distal internal carotid artery aneurysms fairly close
to the base of the skull plus a large renal artery aneurysm with a
history of spontaneous bleeding in the past. So if you’re not going
to use covered stents for those patients, what type of approaches do
you use in these more complex reconstructions, if you do consider
them?
Dr Brooke. We certainly try to use embolization or other
minimally invasive procedures in Ehlers-Danlos patients whenever
they are practical and amenable. Nevertheless, some patients are
only going to be candidates for an open repair due to their specific
anatomic variation or constrictions. Each operative approach is
dependent on the individual patient.
Dr Timothy Kresowik (Iowa City, Iowa). My first comment
relates to your suggested prohibition against the use of stent grafts
in Ehler-Danlos patients when you are treating a spontaneous
disruption rather than performing an aneurysm repair. If you have
a spontaneous disruption of a nonaneurysmal vessel, with good
landing zones, it seems like the stent graft is a much less invasive
and potentially more attractive approach.
Also, in your discussion of endovascular access, you talked
about the use of pledgets or other adjunctive reinforcements for
vessel repair. Are you implying that you always use an open
approach rather than a percutaneous approach? Do you think the
risk of complications is lower with an open approach or could it be
higher?
Dr James Black (Baltimore, Md). Let me clarify something
about the prior questions. I think in general, we agree that the
endovascular safety profile is quite good. I think a lot of that
speaks to lower-profile devices. The prior reports of mortality
rates of 20% to 40% even for a diagnostic arteriogram probably
were related to very large sheath sizes. So for Dr. Dalman’s
question, I think that the advent of newer technologies might
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cular technologies.
Now, on the other side of that, puncture site complications
are very common, and so it’s been our approach that particularly
for the patients that you know are quite fragile, multiple aneu-
rysms, very frequent rate of presentation with aneurysms, that
we do cut down on those femoral vessels. Most of those
procedures, as you might guess, are done under general anes-
thesia for all the concerns about accessing those vessels and
manipulating them.
And just to echo the prior issues of genotype-phenotype, we
have also appreciated that patients as they age, not necessarily
that they remain suitable for surgery, particularly on the vascular
EDS types, their average survival is only 48 years. So while they
might have handled the surgery very well at age 20 or 30, when
they come in again at age 40 and 50, well, they might be at the
end of their life expectancy, and their tissues could be more
fragile. So again, going back to the idea of a skilled medical
geneticist evaluating their tissues is clearly an important part of
our treatment paradigm.
Dr Gustavo Oderich (Rochester, Minn). One of your conclu-
sions was that we should be more liberal in the treatment indications
of aneurysms in patients with vascular EDS. And as you pointed out,
this is a very heterogenous group, and there are patients with more
vascular fragility than others. Sowhatwould you leave as amessage for
everybody here, what should be the indications?
I also have another question regarding the patients that you
didn’t treat, how many patients are you following with surveil-
lance only, and what is the fate of the aneurysms in those
patients?
Dr Black.Well, I think in general the study such as this, when
you talk about patients who are treated or not treated, we sufferwith the referral bias. And for genetic conditions in particular,
referral bias is a double-edged sword. Patients who havemild forms
of the disease, of course, are never referred at all, or they’re handled
in their local institution with relatively little morbidity, versus
patients who are tremendously affected and who probably aren’t
referred at all for the conception that they’re going to have a very
high rate of morbidity. So there is a group of patients that I think
we would have a hard time defining, referring to your question,
Gustavo.
And the other is just in general, a take-home message that
obviously this is – I don’t need to preach to the audience about
doing emergent procedures – but emergent procedures are inher-
ently more difficult. Your options become limited. Our treatment
will focus on patients who have an arterial abnormality that is chang-
ing, such as growing. Our results speak to a high percentage of
patients done electively versus the prior reports from theMayo Clinic
where 70% of the patients were done urgently. And I think that the
differences between our report and that report that’s available in the
Journal of Vascular Surgery are clearly related to that.
So I don’t think we want to ever defer an intervention on a
patient with EDS. If that aneurysm is growing, those patients, given
the window of time, can have a proper genetic evaluation, get a sense
about what the options are. As I said, with the advent of better
technologies, lower-profile, perhaps less traumatic,more flexible stent
grafts,maybe therewill be somewiggle room in the future to consider
stent-graft therapy, but that has not been our approach.
From the standpoint of stent-graft therapy for connective
tissue disorders, there is a pretty strong consensus statement.
Consensus statements actually carry somemedical-legal weight. So
it’s a very tricky ground to be traveling to say we’re going to put a
lot of stent grafts in these patients.
